These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705 [TBL] [Abstract][Full Text] [Related]
10. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Jiang CC; Lai F; Thorne RF; Yang F; Liu H; Hersey P; Zhang XD Clin Cancer Res; 2011 Feb; 17(4):721-30. PubMed ID: 21088259 [TBL] [Abstract][Full Text] [Related]
11. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy. Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796 [TBL] [Abstract][Full Text] [Related]
12. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684 [TBL] [Abstract][Full Text] [Related]
13. PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Deuker MM; Marsh Durban V; Phillips WA; McMahon M Cancer Discov; 2015 Feb; 5(2):143-53. PubMed ID: 25472943 [TBL] [Abstract][Full Text] [Related]
14. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530 [TBL] [Abstract][Full Text] [Related]
15. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Sabbatino F; Wang Y; Wang X; Flaherty KT; Yu L; Pepin D; Scognamiglio G; Pepe S; Kirkwood JM; Cooper ZA; Frederick DT; Wargo JA; Ferrone S; Ferrone CR Oncotarget; 2014 Apr; 5(7):1926-41. PubMed ID: 24732172 [TBL] [Abstract][Full Text] [Related]
16. 3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer. McKinley ET; Smith RA; Zhao P; Fu A; Saleh SA; Uddin MI; Washington MK; Coffey RJ; Manning HC J Nucl Med; 2013 Mar; 54(3):424-30. PubMed ID: 23341544 [TBL] [Abstract][Full Text] [Related]
17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
18. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
19. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Lito P; Saborowski A; Yue J; Solomon M; Joseph E; Gadal S; Saborowski M; Kastenhuber E; Fellmann C; Ohara K; Morikami K; Miura T; Lukacs C; Ishii N; Lowe S; Rosen N Cancer Cell; 2014 May; 25(5):697-710. PubMed ID: 24746704 [TBL] [Abstract][Full Text] [Related]
20. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]